previously few years, the united kingdom has witnessed a revolution in health care bodyweight‑decline treatment options — in the introduction of semaglutide (Wegovy®) for the escalating acceptance of tirzepatide (Mounjaro®). Now, An additional name is drawing interest in both equally clinical and